AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11833837 — intervention group
Group type: COMPARATOR
Intervention: Glyburide 15 mg/d
Number of subjects: 143
Study 11833837 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25 (preprandial)
Number of subjects: 143
Study 11833837 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25 (postprandial)
Number of subjects: 143
Study 11833837 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 143
Study 10050115 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelite dual-cure cement
Number of subjects: 60
Study 10050115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual dual-cure cement
Number of subjects: 60
Study 10050115 — intervention group
Group type: COMPARATOR
Intervention: C&B luting composite (chemically activated cement)
Number of subjects: 60
Study 10050115 — intervention group
Group type: EXPERIMENTAL
Intervention: All cements tested at 7 days
Number of subjects: 60
Study 10050115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cure cements at 90 minutes
Number of subjects: 60
Study 7718549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (CaCO3 tablet, 300 mg Ca)
Number of subjects: 34
Study 7718549 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 34
Study 7718549 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of individual changes in TFCA
Number of subjects: 34
Study 7718549 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential in TFCA between groups after 6 months
Number of subjects: 34
Study 2202200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g/day)
Number of subjects: 89
Study 2202200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulglycotide (600 mg/day)
Number of subjects: 89
Study 2202200 — intervention group
Group type: COMPARATOR
Intervention: Control (Helicobacter pylori colonization)
Number of subjects: 89
Study 7056270 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg b.i.d.
Number of subjects: 8
Study 7056270 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 8
Study 31378665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profile based on fatty acid metabolism and γ‐glutamyl amino acids
Number of subjects: 347
Study 31378665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic risk score based on four metabolites
Number of subjects: 347
Study 31378665 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 347
Study 30170823 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Counseling MOC program
Number of subjects: 102
Study 28987767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heeled footwear (7-11cm)
Number of subjects: 37
Study 28987767 — intervention group
Group type: COMPARATOR
Intervention: Standard control shoes
Number of subjects: 37
Study 26994089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Number of subjects: 243
Study 26994089 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (400 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Number of subjects: 243
Study 26994089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg)
Number of subjects: 243
Study 26994089 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (400 mg)
Number of subjects: 243
Study 25069759 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN α‐2b therapy for ET patients with JAK2V617F(+).
Number of subjects: 259
Study 25069759 — intervention group
Group type: COMPARATOR
Intervention: IFN α‐2b therapy for PV patients with JAK2V617F(+).
Number of subjects: 259
Study 25069759 — intervention group
Group type: COMPARATOR
Intervention: IFN α‐2b therapy for MPDs patients.
Number of subjects: 259
Study 25069759 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN α‐2b therapy.
Number of subjects: 259
Study 22140200 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (2 hours of inpatient physical and occupational therapy focusing on coordination, balance, and ADLs for 4 weeks)
Number of subjects: 42
Study 22140200 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group
Number of subjects: 42
Study 22140200 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same intervention after a 4-week delay)
Number of subjects: 42
Study 20415302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided suprascapular nerve block
Number of subjects: 50
Study 20415302 — intervention group
Group type: COMPARATOR
Intervention: Blind suprascapular nerve block (control)
Number of subjects: 50
Study 17934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal jelly (RJ) supplementation at 6 g per day for 4 weeks
Number of subjects: 15
Study 17934240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 15
Study 17934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal jelly (RJ) supplementation
Number of subjects: 15
Study 15986287 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation for dyspepsia prior to elective heart surgery
Number of subjects: 894
Study 15986287 — intervention group
Group type: EXPERIMENTAL
Intervention: Active peptic ulcer with stigmata of recent bleeding
Number of subjects: 894
Study 15986287 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 894
Study 11932277 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 49
Study 11932277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11932277 — intervention group
Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH) patients compared to controls
Number of subjects: 49
Study 11932277 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SCH) patients
Number of subjects: 49
Study 9866411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60
Study 9866411 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 60
Study 7615227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg per OS three times during the day before the procedure and one 10‐mg dose on the morning of the procedure)
Number of subjects: 84
Study 7615227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearance to cisapride)
Number of subjects: 84
Study 7615227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 84
Study 7615227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 7615227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and Placebo
Number of subjects: 84
Study 2116160 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (4 mg i.v.)
Number of subjects: 30
Study 2116160 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (5 mg)
Number of subjects: 30
Study 755871 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition with auditory signal correlated with EMG responses
Number of subjects: 100
Study 755871 — intervention group
Group type: COMPARATOR
Intervention: Control condition with constant low tone
Number of subjects: 100
Study 755871 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoked-incentive subjects in control condition
Number of subjects: 100
Study 755871 — intervention group
Group type: EXPERIMENTAL
Intervention: No-incentive subjects in control condition
Number of subjects: 100
Study 31356561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 480 mg/min (group A)
Number of subjects: 90
Study 31356561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 240 mg/min (group B)
Number of subjects: 90
Study 31356561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 120 mg/min (group C)
Number of subjects: 90
Study 27794195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task cognitive rehabilitation program (n-back test and PFM exercises)
Number of subjects: 39
Study 27794195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific instructions, no PFM exercises)
Number of subjects: 39
Study 26062881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus lamivudine (300 mg once daily)
Number of subjects: 286
Study 26062881 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus two nucleos(t)ide reverse transcriptase inhibitors
Number of subjects: 286
Study 26062881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment
Number of subjects: 286
Study 26062881 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment
Number of subjects: 286
Study 23748233 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic provision of printed information about psychosocial support services
Number of subjects: 108
Study 23748233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic information)
Number of subjects: 108
Study 21747351 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 180
Study 21747351 — intervention group
Group type: COMPARATOR
Intervention: 1500 nm diode laser
Number of subjects: 180
Study 19250085 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic navigation for catheter ablation
Number of subjects: 38
Study 19250085 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand-controlled catheter ablation
Number of subjects: 38
Study 16415894 — intervention group
Group type: COMPARATOR
Intervention: ATG (Thymoglobulin 2 mg/kg x 3 days)
Number of subjects: 69
Study 16415894 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath (30 mg x 3 days subcutaneously)
Number of subjects: 69
Study 16415894 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath (30 mg once)
Number of subjects: 69
Study 14760948 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta+GA
Number of subjects: 19
Study 14760948 — intervention group
Group type: COMPARATOR
Intervention: IFN‐beta alone
Number of subjects: 19
Study 14760948 — intervention group
Group type: COMPARATOR
Intervention: Untreated MS
Number of subjects: 19
Study 14760948 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 19
Study 11369502 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (400 IU dL-alpha-tocopherol daily)
Number of subjects: 128
Study 11369502 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 11369502 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol
Number of subjects: 128
Study 10717770 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural light/dark cycle (L/Dc) exposure through windows
Number of subjects: 24
Study 10717770 — intervention group
Group type: COMPARATOR
Intervention: No daylight exposure, but access to normal clock time
Number of subjects: 24
Study 8858272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg)
Number of subjects: 8
Study 8858272 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 8
Study 8858272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1517383 — intervention group
Group type: EXPERIMENTAL
Intervention: tiratricol 10 micrograms/kg
Number of subjects: 10
Study 6343022 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training for 5 days
Number of subjects: 12
Study 6343022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation training)
Number of subjects: 12
Study 31955491 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 76
Study 31955491 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 76
Study 29553804 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoring life lessons
Number of subjects: 303
Study 29553804 — intervention group
Group type: COMPARATOR
Intervention: Reflecting on negative aspects of aging
Number of subjects: 303
Study 29553804 — intervention group
Group type: COMPARATOR
Intervention: Untreated-control condition
Number of subjects: 303
Study 29794738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) - 3 sessions/week for 12 weeks
Number of subjects: 40
Study 29794738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) - 1 session/week for 8 weeks
Number of subjects: 40
Study 29794738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AT and MT
Number of subjects: 40
Study 29794738 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study 26536339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-environmental fidelity simulation (HF(en)S)
Number of subjects: 39
Study 26536339 — intervention group
Group type: COMPARATOR
Intervention: Low-environmental fidelity simulations (LF(en)S)
Number of subjects: 39
Study 25005057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-abdominal repair (group 1)
Number of subjects: 1000
Study 25005057 — intervention group
Group type: COMPARATOR
Intervention: In situ repair (group 2)
Number of subjects: 1000
Study 23326650 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) intervention including meal replacements and structured exercise training
Number of subjects: 51
Study 23326650 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) intervention
Number of subjects: 51
Study 23326650 — intervention group
Group type: COMPARATOR
Intervention: Weight stable (WS) group
Number of subjects: 51
Study 20697941 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Xiaozheng Zhitong Paste (XZP) in addition to basic therapy (3L analgesia)
Number of subjects: 124
Study 20697941 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (3L analgesia) without XZP
Number of subjects: 124
Study 20697941 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of XZP
Number of subjects: 124
Study 18260482 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-elbow plaster cast for 3 weeks followed by below-elbow plaster cast for 3 weeks
Number of subjects: 102
Study 18260482 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-elbow plaster cast for 6 weeks
Number of subjects: 102
Study 18260482 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilisation
Number of subjects: 102
Study 15787815 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg daily
Number of subjects: 80
Study 15787815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg daily or 100 mg for 10 days per month if premenopausal
Number of subjects: 80
Study 15787815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antiandrogens (combined results of spironolactone and cyproterone acetate)
Number of subjects: 80
Study 15787815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antiandrogens
Number of subjects: 80
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 39
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG plus GHRH test
Number of subjects: 39
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG plus L-DOPA test
Number of subjects: 39
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG test
Number of subjects: 39
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA test
Number of subjects: 39
Study 11994342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 39
Study 9649640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg
Number of subjects: 30
Study 9649640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9649640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 30
Study 7716041 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary bedside notes
Number of subjects: 0
Study 2653414 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestational agents
Number of subjects: 20
Study 2653414 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 31317576 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination of healthcare workers
Number of subjects: 0
Study 29188876 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte membrane monounsaturated fatty acids (MUFAs) and saturated fatty acids (SFAs)
Number of subjects: 61
Study 24811578 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine every day for 1 month
Number of subjects: 150
Study 24811578 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil on demand 2 hours before intercourse
Number of subjects: 150
Study 24811578 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine and tadalafil on demand 2 hours before intercourse
Number of subjects: 150
Study 24811578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 24100785 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 39
Study 24100785 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 39
Study 21665058 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-FOBT group
Number of subjects: 1372
Study 21665058 — intervention group
Group type: COMPARATOR
Intervention: FLU-only group
Number of subjects: 1372
Study 19390107 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system
Number of subjects: 0
Study 19390107 — intervention group
Group type: COMPARATOR
Intervention: Control units (alerts hidden but tracked)
Number of subjects: 0
Study 16542296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15290412 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 315
Study 15290412 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 315
Study 15290412 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg and 3 mg
Number of subjects: 315
Study 15290412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 11742045 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive‐expressive group therapy
Number of subjects: 235
Study 11742045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 235
Study 9479604 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Duplex Scan (DS)
Number of subjects: 180
Study 9479604 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Duplex Scan (DS)
Number of subjects: 180
Study 9479604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of gastrocnemius veins (GV)
Number of subjects: 180
Study 9479604 — intervention group
Group type: COMPARATOR
Intervention: No ligation of gastrocnemius veins (GV)
Number of subjects: 180
Study 8493295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic (EEG) sleep assessments after successful treatment
Number of subjects: 29
Study 2442826 — intervention group
Group type: EXPERIMENTAL
Intervention: dicumarol (n = 42)
Number of subjects: 463
Study 2442826 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 463
Study 2442826 — intervention group
Group type: EXPERIMENTAL
Intervention: dicumarol in stages III and IV (n = 45)
Number of subjects: 463
Study 2442826 — intervention group
Group type: COMPARATOR
Intervention: Control group in stages III and IV
Number of subjects: 463
Study 31959030 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives plus counseling intervention
Number of subjects: 60
Study 31959030 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives-only intervention
Number of subjects: 60
Study 31959030 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 28468616 — intervention group
Group type: COMPARATOR
Intervention: Real stimulation group
Number of subjects: 55
Study 28468616 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 55
Study 26492477 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg midodrine hydrochloride
Number of subjects: 120
Study 26492477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24200030 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 (generic HRQoL)
Number of subjects: 63
Study 24200030 — intervention group
Group type: EXPERIMENTAL
Intervention: EDQOL (disease-specific HRQoL)
Number of subjects: 63
Study 21436319 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + antifungal
Number of subjects: 92
Study 21436319 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids only
Number of subjects: 92
Study 21436319 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal only
Number of subjects: 92
Study 18297267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus injections (IB) of meropenem 1 g every 12 h
Number of subjects: 6
Study 18297267 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of meropenem 0.5 g loading dose followed by 2 g over 24 h
Number of subjects: 6
Study 16611387 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish meat diet
Number of subjects: 12
Study 16611387 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish meat diet
Number of subjects: 12
Study 16611387 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 12
Study 14623657 — intervention group
Group type: EXPERIMENTAL
Intervention: Active glyceryl trinitrate transdermal patch
Number of subjects: 86
Study 14623657 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 86
Study 10809855 — intervention group
Group type: EXPERIMENTAL
Intervention: Good wound care for 24 weeks
Number of subjects: 104
Study 10809855 — intervention group
Group type: EXPERIMENTAL
Intervention: Good wound care for 4 weeks
Number of subjects: 104
Study 10809855 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of healing (area healed per week)
Number of subjects: 104
Study 8705095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (group 1)
Number of subjects: 126
Study 8705095 — intervention group
Group type: COMPARATOR
Intervention: Conventional open carpal tunnel release (group 2)
Number of subjects: 126